PALETTE- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Bayesian Basket Trial"

PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments. Treatable traits, therapeutic targets identified by phenotypes or endotypes (defined by biological mechanism or by treatment response) through validated biomarkers (measurable characteristic reflecting normal or pathogenic processes, or treatment responses), may include multi-omics, cellular, immune, metabolic, endocrine features, or intelligent algorithms. PALETTE Bayesian adaptive design enables parallel investigations of multiple interventions for sepsis, and quick inclusion of pandemic pathogens. PALETTE's new conceptual model will respond to the challenges of standard approaches, i.e. series of sepsis trials, each investigating one or two interventions, expensive, time consuming, and inappropriate in pandemic context.

开始日期2026-04-01

申办/合作机构

Assistance Publique des Hôpitaux de Paris SA

NCT05251727 / Recruiting临床1期

Double-blind, Placebo-controlled, Randomized, Dose-escalating, Multi-center, Phase 1 Study to Assess the Safety and Tolerability of ART-123 With Leucovorin/5-fluorouracil/Oxaliplatin and Bevacizumab in Metastatic Colorectal Cancer Patients

To evaluate the safety and tolerability of ART-123 in patients with metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy and bevacizumab

开始日期2022-03-24

申办/合作机构

Veloxis Pharmaceuticals A/S

NCT04492436 / Withdrawn临床2期

A Randomized, Double-blind, Placebo-controlled, Multi-national, Multi-center, Parallel-group, Phase 2b Assessing ART-123's Effect on Preventing Sensory Symptoms of OIPN in Unresectable mCRC Subjects Receiving Oxaliplatin-containing Chemo

To evaluate the efficacy and safety of ART-123 on sensory symptoms of oxaliplatin-induced peripheral neuropathy (OIPN) in patients with unresectable metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy

开始日期2021-10-01

申办/合作机构

Veloxis Pharmaceuticals A/S

100 项与血栓调节蛋白α 相关的临床结果

登录后查看更多信息

100 项与血栓调节蛋白α 相关的转化医学

登录后查看更多信息

100 项与血栓调节蛋白α 相关的专利（医药）

登录后查看更多信息

项与血栓调节蛋白α 相关的文献（医药）

2023-12-01·Resuscitation Plus

Coagulofibrinolytic effects of recombinant soluble thrombomodulin in prolonged porcine cardiac arrest

Article

作者: Mahmood, Carmen Colmenero ; Greer, Nicholas ; Neumar, Robert W ; Hsu, Cindy H ; Leander, Danielle ; Greineder, Colin F ; McCracken, Brendan M ; Zhang, Boya ; Cranford, James A ; Tiba, Mohamad Hakam

Aim:

To evaluate coagulofibrinolytic abnormalities and the effects of ART-123 (recombinant human thrombomodulin alpha) in a porcine model of cardiac arrest and prolonged cardiopulmonary resuscitation (CA/CPR).

Methods:

Fifteen pigs (n = 5 per group) underwent 8 minutes of no-flow CA followed by 50 minutes of mechanical CPR, while 2 pigs underwent sham arrest. CA/CPR animals were randomized to receive saline or 1 mg/kg ART-123 pre-arrest (5 minutes prior to ventricular fibrillation) or post-arrest (2 minutes after initiation of CPR). Arterial and venous blood samples were drawn at multiple time points for blood gas analysis and measurement of plasma and whole blood markers of coagulation and fibrinolysis.

Results:

In saline-treated CA/CPR, but not sham animals, robust and persistent activation of coagulation and fibrinolysis was observed throughout resuscitation. After 50 minutes of CPR, plasma tests and thromboelastography indicated a mix of hypercoagulability and consumptive coagulopathy. ART-123 had a robust anticoagulant effect, reducing both thrombin-antithrombin (TAT) complexes and d-dimer (p < 0.05 for each). The duration of anticoagulant effect varied depending on the timing of ART-123 administration. Similarly, ART-123 when given prior to cardiac arrest was found to have pro-fibrinolytic effects, increasing free tissue plasminogen activator (tPA, p = 0.02) and decreasing free plasminogen activator inhibitor-1 (PAI-1, p = 0.04).

Conclusion:

A porcine model of prolonged CA/CPR reproduces many of the coagulofibrinolytic abnormalities observed in human cardiac arrest patients. ART-123 demonstrates a combination of anticoagulant and profibrinolytic effects, depending on the timing of its administration relative to cardiac arrest.

2023-08-01·Shock (Augusta, Ga.)

OPTIMAL PLASMA CONCENTRATION OF THROMBOMODULIN ALFA TO TREAT SEPSIS-INDUCED DISSEMINATED INTRAVASCULAR COAGULATION.

Article

作者: Takayanagi, Risa ; Yamada, Yasuhiko ; Nagase, Satoshi ; Takahashi, Hiroyuki ; Hatoyama-Tanaka, Saori ; Kanno, Hiroshi ; Imaura, Masaharu ; Katagiri, Fumihiko

ABSTRACT:

Thrombomodulin alfa (TM alfa) has been shown effective for treatment of disseminated intravascular coagulation (DIC) associated with sepsis, although the optimal therapeutic plasma concentration has not been clarified. In the present study, the plasma trough concentration of TM alfa in septic patients with DIC was determined, then the cutoff value for that concentration showing influence on treatment outcome was calculated using a receiver operating characteristic curve. With a cutoff value of 1,010, the area under the curve of the receiver operating characteristic was 0.669 (95% confidence interval, 0.530-0.808), with sensitivity of 0.458 and specificity of 0.882. To evaluate its accuracy, patients were divided into those above or below the cutoff value, and 90-day survival rates were compared. The above-cutoff group showed a significantly higher 90-day survival rate (91.7%) as compared with the below-cutoff group (63.4%) ( P = 0.017), with a hazard ratio of 0.199 (95% confidence interval, 0.045-0.871). Interestingly, the incidence of hemorrhagic adverse effects was not significantly different between the groups. Based on these results, the recommended plasma trough concentration of TM alfa for treatment of septic DIC is 1,010 ng/mL, which should minimize the risk of severe bleeding while maximizing the therapeutic effect.

2023-01-01·TH Open

Sepsis-Associated DIC with Decreased Levels of Antithrombin and Fibrinogen is the Target for Combination Therapy with Thrombomodulin Alfa and Antithrombin

Article

作者: Takezako, Naoki ; Madoiwa, Seiji ; Ikezoe, Takayuki ; Okamoto, Kohji ; Kawano, Noriaki ; Suzuki, Kei ; Iba, Toshiaki ; Seki, Yoshinobu ; Kawasugi, Kazuo ; Honda, Goichi ; Wada, Hideo ; Uchiyama, Toshimasa

Background Disseminated intravascular coagulation (DIC) is not a homogeneous condition, but rather includes heterogeneous conditions, and its pathophysiology and outcome vary considerably depending on the background. Although anticoagulant therapy is expected to be of benefit in the treatment of DIC, previous studies have suggested that the benefits are limited only to a specific subtype. Objects The purpose of this study was to identify the group that would benefit from combination therapy using thrombomodulin/antithrombin. Methods The data from 2,839 patients registered in the postmarketing surveillance of thrombomodulin were evaluated. The patients were divided into four groups depending on antithrombin and fibrinogen levels, and the additive effects of antithrombin on thrombomodulin were examined in the groups. Results The DIC score, Sequential Organ Failure Assessment score, and mortality were significantly higher in the DIC group with low-antithrombin/low-fibrinogen than in the DIC groups without either low antithrombin or low fibrinogen. The survival curve was significantly higher in DIC patients with combination therapy than in patients treated with thrombomodulin monotherapy, but this effect was seen only in patients with infection-based DIC. Conclusion DIC patients with low-antithrombin/low-fibrinogen risk poor outcomes, but they can be the target of combination therapy with antithrombin and thrombomodulin as long as the DIC is due to infection.

项与血栓调节蛋白α 相关的新闻（医药）

2021-05-19

·GlobeNewswire

Emerging Drugs for the Chemotherapy Induced Peripheral

Los Angeles, USA , May 19, 2021 (GLOBE NEWSWIRE) -- Emerging Drugs for the Chemotherapy Induced Peripheral Neuropathy Treatment Will Soon Benefit Patients: A Focus on Recent Clinical Trials Chemotherapy-Induced Peripheral Neuropathy Pipeline Report covers a complete clinical trials analysis of 15+ drugs and 15+ companies, which are developing therapies to change the treatment outlook. DelveInsight’s “Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Insight” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Chemotherapy-Induced Peripheral Neuropathy pipeline landscapes. It comprises CIPN pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Chemotherapy Induced Peripheral Neuropathy therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive CIPN pipeline products. Some of the key takeaways of the Chemotherapy Induced Peripheral Neuropathy Pipeline Report Get an overview of pipeline landscape @ CIPN Clinical Trials Analysis Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a common, dose-dependent adverse effect of many frequently prescribed chemotherapy and biotherapy drugs, including taxanes, platinum-based drugs, vinca alkaloids, thalidomide, bortezomib, and interferon. However, there are currently no approved drugs available to prevent or treat CIPN. Certain chemotherapy drugs are more likely to cause neuropathy. These include platinum drugs, such as oxaliplatin; taxanes, such as docetaxel; vinca alkaloids, such as vincristine; and myeloma treatments, such as bortezomib. Other chemotherapy drugs can also cause neuropathy. Chemotherapy-Induced Peripheral Neuropathy Emerging Drugs PledOx (akacalmangafodipir, SP-04), being developed by Pledpharma (now Egetis Therapeutics AB), is a first in class drug candidate developed for the prevention of nerve damage caused by chemotherapy treatment in colorectal cancer patients. Research and DevelopmentPhase III NCT03654729Phase III (POLAR-M): In October 2018, PledPharma initiated a Phase III, multicenter, double-blind, placebo-controlled study to establish the efficacious dose of PledOx in the prevention of chronic chemotherapy-induced peripheral neuropathy (CIPN) induced by oxaliplatin. This Phase III trial enrolled 291 participants and got completed in August 2020. NCT04034355: Phase III (POLAR-A): In November 2018, PledPharm, in collaboration with Solasia Pharma, initiated a phase III, double-blind, multicenter, placebo-controlled study of PledOx used on top of modified FOLFOX6 (5-FU/FA and Oxaliplatin) to prevent CIPN in the adjuvant treatment of patients with stage III or high-risk stage II colorectal cancer. A total of 301 participants were enrolled in this trial, and this trial was completed in August 2020. ART 123 (recombinant human thrombomodulin alpha, marketed as Recomodulin® in Japan), the company’s lead product candidate, represents a promising new treatment for severe sepsis with coagulopathy. ART-123 is a soluble recombinant human thrombomodulin. ART-123 inhibits the coagulation process by accelerating the activation of protein C by thrombin. The drug is currently in phase 2 of clinical trials for the treatment of Chemotherapy-induced Peripheral Neuropathy Research and DevelopmentPhase IINCT04492436: In July 2021, Asahi Kasei Pharma will initiate a trial titled “A Randomized, Double-blind, Placebo-controlled, Multi-national, Multi-center, Parallel-group, Phase 2b Assessing ART-123's Effect on Preventing Sensory Symptoms of OIPN in Unresectable mCRC Subjects Receiving Oxaliplatin-containing Chemo”. The aim of this study is to compare the efficacy and safety of ART-123 (low and high dose) to placebo on sensory symptoms of oxaliplatin-induced peripheral neuropathy (OIPN) in patients with unresectable metastatic colorectal cancer who receive oxaliplatin-containing chemotherapy. The trial is expected to get completed by July 2024. For further information, refer to the detailed report @ Chemotherapy-Induced Peripheral Neuropathy Pipeline Therapeutics Scope of CIPN Pipeline Drug Insight Key Questions regarding Current Chemotherapy-Induced Peripheral Neuropathy Treatment Landscape and Emerging Therapies Answered in the Pipeline Report Table of Contents Get a customised pipeline report @ Chemotherapy-Induced Peripheral Neuropathy Drugs Pipeline Report Related Reports DelveInsight's CIPN - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's Chemotherapy-Induced Peripheral Neuropathy (CIPN) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology. DelveInsight’s ‘Gene Therapy for Ocular Rare Disease -Market Insights, Competitive Landscape and Market Forecast - 2026’ report delivers an in-depth understanding of the disease. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects. DelveInsight’s Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease. DelveInsight' s IgA Nephropathy (IgAN) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. DelveInsight's IgG4-Related Disease- Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology. About DelveInsightDelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Healthcare Consulting services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.

合作小分子药物基因疗法First in Class

100 项与血栓调节蛋白α 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06410	-	B01AX	DB05777

研发状态

适应症	最高研发状态	国家/地区	公司
弥散性血管内凝血	批准上市	日本更多	Asahi Kasei Corp. 更多
周围神经系统疾病	临床1期	美国更多	Veloxis Pharmaceuticals A/S 更多
转移性结直肠癌	临床1期	美国更多	Veloxis Pharmaceuticals A/S 更多
脓毒症	终止	-	Asahi Kasei Pharma America Corp. 更多
凝血障碍	无进展	澳大利亚更多	Asahi Kasei Pharma America Corp. 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02739165 (Pubmed) 人工标引	临床3期	特发性肺纤维化	77	corticosteroid+Thrombomodulin Alfa	憲淵壓構膚艱簾膚網餘(窪淵願艱廠憲繭憲顧衊) = 壓顧鏇繭築範鏇遞襯繭艱遞壓簾築憲壓積餘繭 (醖壓壓蓋願餘鑰顧觸鑰 ) 更多	不佳	2020-05-01
				corticosteroid+Placebo	憲淵壓構膚艱簾膚網餘(窪淵願艱廠憲繭憲顧衊) = 願糧齋鹹餘壓構夢夢積艱遞壓簾築憲壓積餘繭 (醖壓壓蓋願餘鑰顧觸鑰 ) 更多
NCT01598831 (CTgov)	临床3期	凝血障碍 \| 脓毒症	816	ART-123 (ART-123)	壓鏇積餘積構繭製積鏇(窪範簾鏇鬱築蓋襯鬱鑰) = 網膚範鬱鏇艱淵顧鏇糧繭構遞製艱襯糧鏇獵糧 (艱願蓋蓋鑰艱鏇顧窪鹹, 壓窪範艱襯顧顧積願艱 ~ 餘鹽鹹繭遞鹹憲遞膚積) 更多	-	2020-04-21
				Placebo (Placebo)	壓鏇積餘積構繭製積鏇(窪範簾鏇鬱築蓋襯鬱鑰) = 壓艱觸窪選繭製餘艱膚繭構遞製艱襯糧鏇獵糧 (艱願蓋蓋鑰艱鏇顧窪鹹, 蓋鏇廠壓夢築壓膚觸襯 ~ 餘鏇繭積蓋鏇淵遞膚築) 更多
NCT01598831 (SCARLET, Pubmed \| J Coll Physicians Surg Pak) 人工标引	临床3期	脓毒性休克 \| 凝血障碍	800	Recombinant Human Soluble Thrombomodulin	鏇願蓋製鏇選壓築齋憲(醖遞餘網構醖糧壓鹽遞) = 糧鑰觸鹹願獵獵壓鏇淵積簾選遞膚繭網淵壓壓 (築醖廠醖積艱繭憲觸鬱 ) 更多	不佳	2019-05-28
				Placebo	鏇願蓋製鏇選壓築齋憲(醖遞餘網構醖糧壓鹽遞) = 衊襯願簾鏇範繭網蓋鑰積簾選遞膚繭網淵壓壓 (築醖廠醖積艱繭憲觸鬱 ) 更多